Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. (Q37429267)
Jump to navigation
Jump to search
scientific article published on September 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. |
scientific article published on September 2009 |
Statements
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology (English)
M J Li
C X Huang
T Yanhong
1 September 2009
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference